What do you know? The role of race/ethnicity in clinical trial knowledge among patients with a gynecologic malignancy. Read more about What do you know? The role of race/ethnicity in clinical trial knowledge among patients with a gynecologic malignancy.
Cervical cancer treatment in Rwanda: Resource-driven adaptations, quality indicators, and patient outcomes. Read more about Cervical cancer treatment in Rwanda: Resource-driven adaptations, quality indicators, and patient outcomes.
Better late than never: Brachytherapy is more important than timing in treatment of locally advanced cervical cancer. Read more about Better late than never: Brachytherapy is more important than timing in treatment of locally advanced cervical cancer.
Characterization of patients with long-term responses to rucaparib treatment in recurrent ovarian cancer. Read more about Characterization of patients with long-term responses to rucaparib treatment in recurrent ovarian cancer.
Distinct sleep disturbance profiles among patients with gynecologic cancer receiving chemotherapy. Read more about Distinct sleep disturbance profiles among patients with gynecologic cancer receiving chemotherapy.
Trends in the use of cervical cancer screening tests in a large medical claims database, United States, 2013-2019. Read more about Trends in the use of cervical cancer screening tests in a large medical claims database, United States, 2013-2019.
Phase 1b study of AVB-500 in combination with paclitaxel or pegylated liposomal doxorubicin platinum-resistant recurrent ovarian cancer. Read more about Phase 1b study of AVB-500 in combination with paclitaxel or pegylated liposomal doxorubicin platinum-resistant recurrent ovarian cancer.
Text-message-based behavioral weight loss for endometrial cancer survivors with obesity: A randomized controlled trial. Read more about Text-message-based behavioral weight loss for endometrial cancer survivors with obesity: A randomized controlled trial.
Fragmentation of surgery and chemotherapy in the initial phase of ovarian cancer care and its association with overall survival. Read more about Fragmentation of surgery and chemotherapy in the initial phase of ovarian cancer care and its association with overall survival.
Entinostat, a selective HDAC1/2 inhibitor, potentiates the effects of olaparib in homologous recombination proficient ovarian cancer. Read more about Entinostat, a selective HDAC1/2 inhibitor, potentiates the effects of olaparib in homologous recombination proficient ovarian cancer.
